你打的减肥针，撑起了万亿美元巨头

Core Insights - The article discusses the significant rise of Eli Lilly, driven by the success of its weight loss drug, Tirzepatide, which has surpassed cancer drugs to become the highest-grossing medication globally [1][2] - Eli Lilly's market capitalization has reached over $1 trillion, making it the first pharmaceutical company to achieve this milestone, largely due to the GLP-1 phenomenon [2][3] Company Overview - Eli Lilly, founded in 1876, has a long history in the pharmaceutical industry, initially gaining prominence with insulin production in the 1920s [3] - The company has recently revitalized its position in the market through the development of GLP-1 drugs, particularly Tirzepatide, which has been a game-changer for its revenue [4][6] Market Performance - Tirzepatide generated $10.103 billion in sales during the third quarter of 2025, making it the top-selling drug globally [2][6] - The drug has contributed approximately 60% of Eli Lilly's revenue, which was around $458.87 billion in the first three quarters of 2025, ranking it first among multinational pharmaceutical companies [6][7] Competitive Landscape - The GLP-1 market remains unsaturated, with significant potential for growth as obesity and diabetes rates rise globally [7][8] - Eli Lilly's Tirzepatide is positioned to compete effectively against Novo Nordisk's Semaglutide, with clinical trials showing superior efficacy in both weight loss and blood sugar control [6][8] Future Prospects - Eli Lilly is focusing on expanding its GLP-1 portfolio, including oral formulations to address production capacity issues and reach a broader market [8][9] - The company plans to invest $14 billion in research and development, aiming to launch new drugs annually over the next several years [11][12]